ESC 2019 Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.
ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.
ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.
The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.
ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.
ESC 2019 Brief impression of the new ESC recommendations on acute pulmonary embolism, supraventricular tachycardia and chronic coronary syndromes.
ESC 2019 Erik Björklund summarizes findings from long-term data of the SWEDEHEART registry on use of secondary prevention therapies and association with mortality.
ESC 2019 Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.
ESC 2019 Selection of an oral P2Y12 inhibitor based on a genetic test for a loss-of-function allele that makes people non-responsive to clopidogrel did not increase stent thrombosis and reduced bleeding events.
ESC 2019 Data from SWEDEHEART show that use of statins, RAAS-inhibitors and platelet inhibitors is associated with a significant reduction in mortality risk, while beta-blockers were not.
ESC 2019 Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.
ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.